The Global Market for Cholesterol Testing is Projected to Reach 3.4 Billion Tests by 2022

Preventive Healthcare Trends & Expansion of High Risk Population Drive the Global Cholesterol Testing Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry trends, growth drivers, market share, size and demand forecasts on the global Cholesterol Testing market. The global market for Cholesterol Testing is projected to reach 3.4 billion tests by 2022, driven by the surge in risk of CVD in obese, diabetic, hypertensive, and ageing population.

Cholesterol tests are essential to measure the level of cholesterol carrier or lipoprotein in the blood. High levels of LDL or bad cholesterol is a known risk factor for cardiovascular disease (CVD), rated as the leading cause of death worldwide. The menace of CVD has assumed mammoth proportions with the disease claiming the life of an individual every 39 seconds in the U.S. alone. The burden of CVD on the healthcare system include the cost of physician and nursing services, hospital and nursing home services, the cost of medications and lost productivity resulting from disability. Cardiovascular diseases encompass high blood pressure or hypertension, coronary heart disease, stroke and rheumatic heart disease. The growth in the cholesterol testing market is stimulated by growing awareness over the importance of testing as a measure to reduce fatality and improve diagnosis and treatment of CVD.

Rising disposable income levels, coupled with increasing urbanization, growing health consciousness, aging population, and growing awareness of the need for cardiovascular risk assessments such as cholesterol testing are fuelling demand for CVD risk assessment techniques. The rise in incidence of lifestyle diseases such as obesity, diabetes, and hypertension, all regarded as major risk factors for cardiovascular disease prompted by changing food habits and increasing preference for processed foods & beverages will drive growth in the market. A large proportion of cardiovascular complications are also attributed to genetic inheritance from parents, known as Familial Hypercholesterolemia (FH). The increasing preference for preventive healthcare as well as improved access to healthcare is also credited with promoting cholesterol testing. Healthcare spending in emerging markets, such as India, China, Indonesia, Mexico, and Russia is increasing primarily due to the supportive demographic trends and government initiatives. While India and China are likely to post healthy annual growth on healthcare expenditure, spending in developed countries is expected to exhibit an impressive growth due to strong medical insurance systems. Technological advancements resulting in miniaturization of devices is expected to essay a crucial role in driving demand for self-testing kits. Growth is further expected from increasing preference for home testing and the subsequent availability of OTC (over-the-counter) cholesterol test kits.

As stated by the new market research report on Cholesterol Testing, Asia-Pacific ranks as the largest and the fastest growing market worldwide supported by developing healthcare infrastructure; growing base of at-risk population in emerging nations such as China, India, and Singapore; and growing awareness over the importance of risk estimation and prevention of cardiovascular diseases.

Key players covered in the report include Abbott Diagnostics, Inc., AccuTech, LLC, Alere Inc., Beckman Coulter, Inc., Home Access Health Corporation, PTS Diagnostics, Roche Diagnostics, and Siemens Healthineers, among others.

The research report titled “Cholesterol Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections in dollars for all major geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, and Rest of Asia-Pacific), Latin America (Brazil, and Rest of Latin America), and Rest of World. Test Types analyzed in the report include Lipid Panel Test/Complete Lipid Profile, Apolipoprotein B Test, and Other Cholesterol Tests.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.